Pulse Biosciences, Inc. (PLSE) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on July 15, 2024, by Pulse Biosciences, Inc. The filing discloses the entry into a material definitive agreement and provides preliminary, unaudited financial results for the three months ended June 30, 2024.
Key Financial Metrics (Preliminary Estimates)
The following metrics represent estimated ranges for the quarter ended June 30, 2024, as final closing procedures were not complete at the time of filing. All figures are in millions unless otherwise noted.
| Metric | Low Estimate | High Estimate |
|---|---|---|
| Cash and Cash Equivalents | $26.0 | $26.5 |
| GAAP Costs and Expenses | $11.0 | $13.0 |
| GAAP Net Loss | $(10.7) | $(12.7) |
| Non-GAAP Costs and Expenses | $9.0 | $10.0 |
| Non-GAAP Net Loss | $(8.7) | $(9.7) |
Note: Cash and cash equivalents exclude $60.0 million in proceeds received from a rights offering closed in July 2024. The filing does not provide specific revenue figures, debt balances, or liquidity ratios beyond the cash position.
Material Changes and Agreements
- Equity Distribution Agreement: On July 15, 2024, the Company entered into an agreement with Canaccord Genuity LLC and Needham & Company, LLC to sell up to $60.0 million of common stock via "at-the-market" offerings.
- Commission: The Company will pay the sales agents a commission of up to 3.0% of the gross sales price per share.
- Flexibility: The Company is not obligated to sell any shares and may suspend offers at any time.
- Registration: Sales will be made pursuant to effective Form S-3 registration statements filed in March and July 2024.
Guidance, Outlook, and Risks
The filing contains forward-looking statements regarding the preliminary financial results. Management cautions that actual results may differ materially due to risks and uncertainties. The preliminary figures are subject to adjustment upon completion of final closing procedures and management review. The independent auditor, Deloitte & Touche LLP, has not audited or reviewed these preliminary results.
Non-GAAP measures exclude stock-based compensation and depreciation/amortization to aid in monitoring ongoing operations. Investors are advised to review the reconciliation of GAAP to Non-GAAP measures provided in the filing.
Key Facts for Investor Verification
- Verify the final audited financial results for the quarter ended June 30, 2024, once the official 10-Q is filed, as current figures are preliminary estimates.
- Confirm the total cash position including the $60.0 million from the July 2024 rights offering, which is excluded from the preliminary cash balance.
- Monitor the execution of the new $60.0 million equity distribution agreement and the impact of share sales on dilution.
- Review the specific components of stock-based compensation and depreciation/amortization in the final reconciliation to understand the variance between GAAP and Non-GAAP losses.